Market Winds – Small Entries

         

Market Talk

Market Winds – Small Entries

The market feels headline-driven right now. Big names moving on every twist — up one minute, hit the next. That kind of action can shake people out or pull them into bad entries.

Sometimes the better move is smaller, controlled entries where the story is still forming.

One name worth a look in that light — Oncolytics Biotech (ONCY).

Here’s the setup:

• GOBLET study showed complete responses (CRs) and durable activity in anal cancer

• In CRC, pelareorep is showing positive signals in KRAS-mutant disease that are getting attention

• The company is now prioritizing registration-focused programs in both anal cancer and CRC

• Combining pelareorep with Avastin in CRC, and with Tecentriq in anal cancer

• A newly launched randomized Phase 2 CRC trial pairing pelareorep with Avastin and FOLFIRI moves that part of the story forward

And now:

• New data being presented at AACR is framing pelareorep as an immune-priming backbone — activating T-cells, reshaping the tumor environment, and potentially improving response across combination regimens

That last part matters. If it starts to be viewed as a platform that enhances other therapies, not just a standalone drug, the story can change quickly.

The question now is whether they show the full immune mechanism — not just the signals.

Who knows what twists and turns the story may take.

No guarantees here — biotech never gives you that.

Small entries leave room for dry powder while staying mildly involved.

At just about $1 a share — if you’re up for speculation — small entries only.

- Jones Report

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.
________